Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

NCT02015520 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

143

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Clazakizumab
DRUG: Placebo (Matching with Clazakizumab)

Sponsor

CSL Behring